| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | METHODS OF DETECTING ANALYTES AND DIAGNOSING TUBERCULOSIS | US15550183 | 2016-02-10 | US20180031584A1 | 2018-02-01 | Marc D. PORTER; Jennifer H. GRANGER; Alexis C. CRAWFORD; Lars Bjorn LAURENTIUS |
| A method for detecting lipoarabinomannan in a biological sample is described, including the step of contacting the biological sample with at least one acid selected from the group consisting of perchloric acid, trifluoroacetic acid, and sulfosalicylic acid. Methods for diagnosing diseases, including tuberculosis, and kits for the described methods are also presented. | ||||||
| 162 | METHOD OF FORMING A LIPID BILAYER | US15526919 | 2015-11-19 | US20170356897A1 | 2017-12-14 | Dac Nguyen; Basil Hanss |
| The present application is directed, at least in part, to a process for forming droplet interface blayers (DIBs). In one or more embodiments, a housing is produced wherein the housing includes at least one aperture that comprises a cis portion and a trans portion, at least one cis electrode receptacle and at least one trans electrode receptacle, wherein the cis electrode receptacle is operatively connected to the cis portion, and the trans electrode receptacle is operatively connected to the trans portion. In at least one embodiment, the number of cis and trans electrode receptacles equals the number of apertures. Electrodes are treated with a buffer and then inserted into each of the cis and trans electrode receptacles. | ||||||
| 163 | METHODS AND SYSTEMS FOR METABOLITE AND/OR LIPID-BASED DETECTION OF COLORECTAL CANCER AND/OR ADENOMATOUS POLYPS | US15458568 | 2017-03-14 | US20170343567A1 | 2017-11-30 | Marko Bitenc; Kristi Kruusmaa; Paola Hurtado Castillo; Ana María Jiménez Girón; Rosa Argamasilla Martinez; Andreu Fabregat Rossell; Antonio Jesus Adsuar Gomez; Juan Martinez-Barea; Christian Hense; Patricia Rodríguez Gómez; Ángela Peralbo Molina; Jorge Casado Agrelo; Alejandro Sánchez Brotons; Cristina Pavón Solís; Rosa María Delgado Sánchez |
| Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot. | ||||||
| 164 | 9-oxo-ODE as a biomarker for healthy aging | US14491396 | 2014-09-19 | US09817003B2 | 2017-11-14 | Sebastiano Collino; Ivan Montoliu Roura; Francois-Pierre Martin; Philippe Alexandre Guy; Serge Andre Dominique Rezzi |
| Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-ODE as biomarker. | ||||||
| 165 | IMMUNOASSAYS FOR THE DIFFERENTIATION OF BACTERIAL PATHOGENS IN HUMAN SERUM | US15640865 | 2017-07-03 | US20170307604A1 | 2017-10-26 | Harshini Mukundan; Jessica Kubicek-Sutherland; Shailja Jakhar; Aneesa Noormohamed; Basil I. Swanson; Rama Murthy Sakamuri; Loreen Stromberg |
| Systems for and methods of capturing, detecting, quantifying, and characterizing target moieties that are characterized by having a lipophilic portion of sufficient size and chemical composition whereby the target moiety inserts (or partitions) into a lipid assembly are described. Methods of diagnosing a subject as having a bacterial infection by detecting bacterial pathogen associated molecular pattern (PAMP) molecules in serum are further described. | ||||||
| 166 | Means and Methods for Diagnosing Heart Failure in a Subject | US15507801 | 2015-09-01 | US20170285049A1 | 2017-10-05 | Philipp Schatz; Henning Witt; Martin Dostler; Susan Carvalho; Erik Peter; Philipp Ternes; Philipp Mappes; Hans Dirk; Tobias Daniel; Elvis Tahirovic; Hugo Katus; Norbert Frey; Tanja Weis |
| The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. | ||||||
| 167 | METHOD FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT | US15315078 | 2015-06-01 | US20170242040A1 | 2017-08-24 | Carlo Zanotti; Andres Rodriguez Martin; Luis Gil De Gomez Sesma |
| The invention relates to methods for determining the likelihood that a patient with mild cognitive impairment develops Alzheimer's disease based on the determination of the levels of different metabolites, including amino acids, proteins and lipids. The invention also provides a method for diagnosing Alzheimer's disease or mild cognitive impairment in a subject based on the determination of the above metabolites. | ||||||
| 168 | METHOD AND KIT FOR DETECTION OF MYCOBACTERIA | US15503647 | 2015-08-13 | US20170242005A1 | 2017-08-24 | Mark Stephen Baird; Christopher David Gwenin; Vanessa Valerie Gwenin; Alison Jones |
| A method of determining whether an individual is infected with mycobacteria. The method comprising the steps of (a) providing a system which comprises at least two different mycolic-acid derived antigens; (b) introducing a sample obtained from the individual into the system and into contact with each of the at least two different mycolic-acid derived antigens; and (c) detecting the presence or absence of the binding of a biomarker in the sample with each antigen in the system. The method may be particularly suitable for determining the presence or absence of a disease antibody indicative of infection with any disease caused by infection with mycobacteria, for example tuberculosis, leprosy, pulmonary disease, burili ulcer, Johne's disease and bovine tuberculosis. A kit and device are also described. The present invention may provide an over the counter device to allow individuals to check on a routine basis that they have normal immune responses. | ||||||
| 169 | Compositions of Matter that Reduce Pain, Shock, and Inflammation by Blocking Linoleic Acid Metabolites and Uses Thereof | US15444706 | 2017-02-28 | US20170204415A1 | 2017-07-20 | Kenneth Michael Hargreaves; John Gordon Bruno |
| A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs. | ||||||
| 170 | Heptadecanoic acid supplement to human diet | US14980304 | 2015-12-28 | US09707199B2 | 2017-07-18 | Stephanie Venn-Watson |
| Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight. | ||||||
| 171 | METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF STRUCTURALLY DIVERSE COMPLEX LIPIDS | US15251579 | 2016-08-30 | US20170192023A1 | 2017-07-06 | Steven Watkins |
| Methods are provided for synthesizing mixtures of lipids that are representative of the structural diversity of the lipids present in samples of interest. The complex mixtures of lipids produced according to the methods of the present disclosure can be used as internal standards for detecting and quantifying the lipids in samples of interest. Kits including the internal standards and instructions for their use in the detection and quantification of lipids in samples of interest are also provided. | ||||||
| 172 | Use of MicroRNA or inhibitors thereof in regulation of lipid metabolism | US14763902 | 2014-01-26 | US09616086B2 | 2017-04-11 | Bin Hong; Li Wang; Xiaojian Jia; Huajun Jiang; Yu Du; Fan Yang; Shuyi Si |
| The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases. | ||||||
| 173 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT | US15249935 | 2016-08-29 | US20160363602A1 | 2016-12-15 | Reijo Laaksonen; Kim Ekroos; Reini Hurme; Riikka Katainen |
| The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | ||||||
| 174 | CHOLESTEROL EFFLUX CAPACITY ASSESSMENT | US14744729 | 2015-06-19 | US20160327579A1 | 2016-11-10 | Bela F. Asztalos; Michael Riel-mehan; Ernst J. Schaefer |
| A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) value. Methods relate to determining SR-BI-mediated and ABCA1-mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens. | ||||||
| 175 | Cosmetic compositions | US14694128 | 2015-04-23 | US09480634B2 | 2016-11-01 | Sourav Das; Naohisa Yoshimi; Shuhei Tanaka |
| A cosmetic composition comprising a safe and effective amount of a skin care active; a safe and effective amount of a skin lightening agent; a safe and effective amount of bisabolol; and a safe and effective amount of a glycerol ether of aliphatic alcohol, wherein the ratio of bisabolol to glycerol ether of aliphatic alcohol is from 2:1 to 1:15. | ||||||
| 176 | LIPID BIOMARKERS OF HEALTHY AGEING | US15028244 | 2014-11-05 | US20160245786A1 | 2016-08-25 | Sebastiano Collino; Ivan Montoliu Roura; Françios-Pierre Martin; Fiona Camille Beguelin; Serge André Dominique Rezzi |
| In one aspect there is provided a method for predicting a risk of unhealthy ageing in a subject, comprising: (a) determining a level of two or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from two or more of the following groups: (i) a triacylglycerol (TAG) from TAG (46:5) to TAG (54:3); (ii) an ether phosphatidylcholine (PC-O) from PC-O(28:0) to PC-O(38:6); (iii) a sphingomyelin (SM) from SM (33:1) to SM(50:1); (iv) a phosphatidylcholine (PC) from PC (32:1) to PC (40:5); (v) a phosphatidylinositol (PI) from PI (36:1) to PI (38:3); (vi) a phosphatidylethanolamine (PE) from PE (36:2) to PE (38:4); and (b) comparing the levels of the biomarkers in the sample to reference values; wherein the levels of the biomarkers in the sample compared to the reference values are indicative of the risk of unhealthy ageing in the subject. | ||||||
| 177 | Method for Monitoring Heptadecanoic Acid in Human and Animal Samples | US14980167 | 2015-12-28 | US20160195558A1 | 2016-07-07 | Stephanie Venn-Watson |
| Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight. | ||||||
| 178 | Means and Methods for Assessing Increased Peroxisomal Proliferation | US15053189 | 2016-02-25 | US20160169863A1 | 2016-06-16 | Bennard van Ravenzwaay; Werner Mellert; Eric Fabian; Volker Strasse; Tilmann Walk; Ralf Looser; Edgar Leibold; Hennicke Kamp; Georgia Coelho Palermo Cunha; Michael Herold; Jan C Wiemer; Alexander Prokudin |
| The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject. | ||||||
| 179 | CARDIOVASCULAR DISEASE RISK ASSESSMENT | US14943775 | 2015-11-17 | US20160139160A1 | 2016-05-19 | Ernst J. Schaefer |
| The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers LDL and HDL subfractions, along with Lp(a) provides significant improvement in predicting CVD versus standard assays that include standard risk factors. Methods of the invention comprise measuring LDL and HDL subfractions in addition to Lp(a) without reference to standard risk factor measurements, such as CRP, total cholesterol, body mass index, weight, triglycerides, and the like. It is unexpected that an algorithm focusing only on LDL and HDL subfractions and Lp(a) would be more informative as to CVD risk than measurements that are much more comprehensive in terms of the markers that are reviewed. In particular, the sdLDL-C subfraction of LDL and the ApoA-1 in large alpha-1 HDL are most informative in conjunction with Lp(a). | ||||||
| 180 | METHOD OF MEASURING LIPOPROTEIN'S CAPACITY TO ACCEPT CHOLESTEROL | US14882812 | 2015-10-14 | US20160109469A1 | 2016-04-21 | Amane HARADA; Katsuhiro MURAKAMI; Maria KIRIYAMA; Keiko YOSHIKAWA; Keiko MIWA |
| Provided is a method of measuring a lipoprotein's capacity to accept cholesterol including the steps of: bringing a lipoprotein in a sample into contact with labeled cholesterol to incorporate the labeled cholesterol into the lipoprotein; bringing the lipoprotein having the labeled cholesterol into contact with an antibody that binds to a lipoprotein to form a complex of the lipoprotein and the antibody; and measuring the label incorporated into the complex. | ||||||
QQ群二维码
意见反馈
意见反馈